Evidence map›Paper›PMID 42329347›Full record

ArticleInvestigational new drugs2026

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.

William P Harris, Pilar García-Alfonso, Jean Phillipe Metges, Antonio Cubillo-Gracian, Aziz Zaanan, Lopez Lopez Carlos, Monica Ronzoni, Mariano Ponz-Sarvise, Adyb Baakili, Asma Kefsi and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

William P HarrisUniversity of Washington Medical Center, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Pilar García-AlfonsoMedical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, Madrid, Spain.
Jean Phillipe MetgesInstitut de Cancérologie et d'Imagerie CHU Cavale Blanche ARPEGO NETWORK, Brest, France.
Antonio Cubillo-GracianHM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.
Aziz ZaananDepartment of Digestive Oncology, Georges Pompidou European Hospital, Assistance Publique - Hôpitaux de Paris, University of Paris Cité, Paris, France.
Lopez Lopez CarlosHospital Universitario Marques de Valdecilla, IDIVAL, UNICAN, Santander, Spain.
Monica RonzoniVita-Salute San Raffaele University, Milan, Italy.
Mariano Ponz-SarviseDepartment of Medical Oncology and Program in Solid Tumors, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.
Adyb BaakiliSanofi-Aventis Recherche & Développement, Paris, France. adyb.baakili@sanofi.com.ORCID http://orcid.org/0009-0003-9560-4631
Asma KefsiSanofi-Aventis Recherche & Développement, Paris, France.
Laurent AndrieuSanofi-Aventis Recherche & Développement, Paris, France.
Maria AgrawalSanofi, Cambridge, MA, USA.
Wenting WangSanofi, Cambridge, MA, USA.
Tobias PaehlerSanofi-Aventis Deutschland, Frankfurt, Germany.
Giovanni AbbadessaSanofi, Cambridge, MA, USA.
Eric Van CutsemUniversity Hospitals Gasthuisberg, University of Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pegenzileukin (SAR444245) is a pegylated recombinant human IL-2 variant designed to expand effector T cells and NK cells without stimulating regulatory T cells. This study evaluated pegenzileukin with pembrolizumab or cetuximab for treating advanced gastrointestinal cancers. A total of 138 patients with advanced gastric cancer (GC), colorectal carcinoma, esophageal squamous cell carcinoma (ESCC), and hepatocellular carcinoma (HCC) were enrolled across seven cohorts in this phase 2 study. Patients received pegenzileukin (24 µg/kg every 3 weeks [Q3W]) with pembrolizumab (200 mg Q3W) or cetuximab (initially 400 mg/m

Indexed as

CetuximabGastrointestinal cancerInterleukin-2PEGATHORPegenzileukinPembrolizumabSAR444245

Identifiers

PMID42329347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.